Arabic Arabic English English French French German German
dark

Jacobio Announces Strategic Investment in Hebecell to Further Develop iPSC-NK Cell Therapy

Jacobio Pharmaceuticals (“Jacobio”, 1167.HK) announced a strategic investment in the US-based biotech company Hebecell on August 31 . Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Departure of Founder and CEO Heightens Uncertainty for Galapagos

Next Post

Medivir receives regulatory approval from MHRA for phase 1/2a combination study with MIV-818

Related Posts
Total
0
Share